The NEOS study updated the results of osimertinib as neoadjuvant therapy in patients with EGFR-mutated resectable stage II-IIIB lung adenocarcinoma at the 2022 European Society for Medical Oncology (ESMO) Congress, thus, further supporting the advantages of osimertinib over other EGFR-TKIs (15). Here, EGFR is linked to lung adenocarcinoma.